An executive order by Trump rolled back some efforts by the Biden administration to control Medicare costs but it didn't ...

Where the previous Trump administration removed five regulations for every new one, the target is now 10. Our research shows ...

An interview with former White House communications strategist Andrew Bates, who explains how Democrats can capitalize on ...

Manufacturers are responsible for meeting all four parts of the definition of bona fide service fee before a fee can qualify as a bona fide ...

Speaker Mike Johnson (R-La.) indicated this week that his approach to repealing the Democrats’ climate, tax, infrastructure ...

At least three government lawyers working on defending a major Biden-era drug pricing law were laid off in mass cuts across ...

Prior authorization reforms, increased biosimilar access and the future of the Medicare drug price negotiation program are ...

The bill would allow Medicare to begin negotiating with pharmaceutical companies over prices for small molecule medicines 13 ...

A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it ...

Merck (NYSE:MRK) said it expects its top-selling drug, Keytruda, to be selected by the U.S. government for price setting ...